Colaluca, I.N.* ; Basile, A.* ; Freiburger, L. ; D'Uva, V.* ; Disalvatore, D.* ; Vecchi, M.* ; Confalonieri, S.* ; Tosoni, D.* ; Cecatiello, V.* ; Malabarba, M.G.* ; Yang, C.J.* ; Kainosho, M.* ; Sattler, M. ; Mapelli, M.* ; Pece, S.* ; di Fiore, P.P.*
A Numb-Mdm2 fuzzy complex reveals an isoform-specific involvement of Numb in breast cancer.
J. Cell Biol. 217, 745-762 (2018)
Numb functions as an oncosuppressor by inhibiting Notch signaling and stabilizing p53. This latter effect depends on the interaction of Numb with Mdm2, the E3 ligase that ubiquitinates p53 and commits it to degradation. In breast cancer (BC), loss of Numb results in a reduction of p53-mediated responses including sensitivity to genotoxic drugs and maintenance of homeostasis in the stem cell compartment. In this study, we show that the Numb-Mdm2 interaction represents a fuzzy complex mediated by a short Numb sequence encompassing its alternatively spliced exon 3 (Ex3), which is necessary and sufficient to inhibit Mdm2 and prevent p53 degradation. Alterations in the Numb splicing pattern are critical in BC as shown by increased chemoresistance of tumors displaying reduced levels of Ex3-containing isoforms, an effect that could be mechanistically linked to diminished p53 levels. A reduced level of Ex3-less Numb isoforms independently predicts poor outcome in BCs harboring wild-type p53. Thus, we have uncovered an important mechanism of chemoresistance and progression in p53-competent BCs.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Cell Fate; Mammalian Numb; Lung-cancer; Ubiquitin Ligase; Nmr Experiments; Histone H2ax; P53 Pathway; Case-cohort; Dna-damage; Mdm2
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2018
Prepublished im Jahr
2017
HGF-Berichtsjahr
2017
ISSN (print) / ISBN
0021-9525
e-ISSN
1540-8140
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 217,
Heft: 2,
Seiten: 745-762
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
Rockefeller University Press
Verlagsort
New York
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-503000-001
Förderungen
Copyright
Erfassungsdatum
2018-02-21